IPA.V - ImmunoPrecise Antibodies Ltd


#142

ImmunoPrecise Announces Phage DisplayBased Antibody Discovery Platforms

VICTORIA, Oct. 2, 2018

VICTORIA, Oct. 2, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage libraries to their growing service offeringsthrough their recent expansion in Europe. Through construction and screening of scFv and VHH phage display libraries, ImmunoPrecise is able to generate monoclonal antibodies, in a diverse range of animal species, against complex protein structures.

The Company offers access to proprietary in-house human and llama VHH phage libraries, applicable for non-immunogenic and toxic targets, the construction of custom immune libraries prepared from a diverse range of animal species, and synthetic phage libraries generated for state-of-the-art humanization and affinity maturation procedures to optimize lead candidates for clinical trials. Access to their royalty-free human scFv and llama VHH repertoires, along with expertise in protein and antibody engineering, positions the Company as a desirable provider for bispecific antibody development.

A Powerful Method for Therapeutic Antibody Development

Antibody phage display uses genetically engineered bacteriophage to express a single antibody fragment sequence on their outer surface, allowing isolation of the antibody-bound phage with the required characteristics by selection on the target.

Through phage display, ImmunoPrecise is able to offer another avenue of therapeutic antibody discovery; positioning them as a full-service CRO offering the full continuum of antibody discovery, manufacturing and engineering, to deliver a broad and diverse panel of antibodies for therapeutic campaigns.

Phage Advantages

Diversity - Specificity - Stability

  • Access to naïve and disease human, and naïve llama immune repertoires from in-house libraries
  • Custom immune libraries prepared from blood, spleen, lymph nodes, and bone marrow of a diverse range of immunized animals
  • Llama VHH antibodies offer high stability and small size
  • Allows high specificity selection to obtain a large diverse, highly specific antibody repertoire for full characterization
  • Unlimited re-screening of the library repertoires
  • Library-derived sequences for bispecific antibody development in multiple formats

#143

Le support à 0.83$ vient de briser…on s’en va vers le prochain support à 0.72$ sinon le prochain est à 0.54$.

À suivre


#144

ImmunoPrecise Signs Large Pharma Antibody Development Agreement

VICTORIA, Oct. 9, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company, to discover novel antibodies using ImmunoPrecise’s proprietary hybridoma technology.

ImmunoPrecise’s hybridoma platform allows for the selection of rare and slow-growing, IgG positive, monoclonal hybridomas in a semi-solid media format. Coupled with proprietary and abbreviated immunization regimes, the ability to sort cells and characterize and optimize lead candidates, ImmunoPrecise’s platform allows for streamlined processes, condensed timelines, and the early identification of developability issues, mitigating the risk of significant losses in time and money.

Under this multi-year development agreement, this global pharmaceutical company receives contract research services using ImmunoPrecise’s methods of discovering and developing antibodies in OmniAb® transgenic animals (Ligand Pharmaceuticals, NASDAQ: LGND), and intellectual property rights to develop and commercialize any resulting therapeutics.

The Agreement stipulates certain confidential provisions, including, at this stage, the pharmaceutical company’s identity, target and the monetary size of contract.

ImmunoPrecise is currently in negotiations with several top 10 global pharmaceutical companies investigating the use of ImmunoPrecise’s three full-service platforms, its advanced hybridoma platform, its proprietary and high demand B-cell selectplatform, and its phage display library platform. All three can be optimally leveraged for antibody discovery using various transgenic and wild-type animal strains.

“ImmunoPrecise can uniquely leverage three powerful platforms for antibody discovery to offer comprehensive campaigns that have the potential to deliver the antibody sequence diversity required to rapidly select the best lead candidates for further advancement” said Jennifer Bath, CEO and President of ImmunoPrecise Antibodies. "We’ve seen very strong interest in our diverse line of development platforms from a number of leading global pharmaceutical and biotech companies. "


#145

La baisse a été de relativement courte durée, avec le titre qui a clôturé a 0.88 vendredi et qui est maintenant de retour dans les bas 0.90. L’annonce d’un gros contrat (voir @SimB) le ramènera probablement au dessus de la barre des 1.00 sous peu.


#146

On a flirté brièvement avec le support à 0.72$ pour finir à .74$. Si 0.72$ brise on s’en va au prochain support à 0.54$ ce qui pourrait donner un point d’entrée intéressant


#147

ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform

VICTORIA, Oct. 29, 2018 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is excited to expand its immunization services through our recent growth in Europe. Our advanced genetic immunization strategies are applicable in multiple species, including transgenics, and across all discovery platforms. We have developed our genetic immunization protocol with our proprietary vectors to meet the growing demand for therapeutic antibodies against challenging, conformation-sensitive drug targets.

Through our in-house developed vectors, our protocol produces native protein with appropriate post-transcriptional modifications in vivo. Clients are not subject to downstream milestones or royalties, and bypass the requirement to purify protein or synthesize peptide for immunization.

Custom Developed Antibodies for Difficult Targets

Genetic immunization is a recommended protocol to compliment challenging campaigns against complex protein classes, such as GPCRs and ion channels. It overcomes the conformation obstacles of difficult antigens making it an ideal immunization platform in therapeutic discovery campaigns.

Genetic Advantage:

  • Overcomes conformational obstacles of complex transmembrane protein classes (e.g. GPCRs and ion channels)
  • Successful in multiple species, including transgenics
  • Time-saving when compared with traditional protein-based immunizations, since it avoids the lengthy process of expressing and purifying the immunogen

“ModiQuest’s long-standing expertise in advanced genetic immunization technologies is a strategic addition, designed specifically to deliver an unprecedented and growing arsenal of immunization approaches to tackle challenging therapeutic targets”, stated ImmunoPrecise’s President and CEO, Dr. Jennifer Bath.

ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform (CNW Group/ImmunoPrecise Antibodies Ltd.)

Debt Settlement

ImmunoPrecise announces that it has settled $1,377,000 of previously issued debentures by issuing 1,377,000 Units at a price of $1.00 per Unit (the “Debt Settlement”). The purpose of the Debt Settlement is to shore up ImmunoPrecise’s balance sheet by removing ongoing debt obligations related to $1,377,000of debentures.

Each Unit consists of one common share (a “Share”) of ImmunoPrecise and one share purchase warrant (a “Warrant”) of ImmuoPrecise, with each Warrant entitling the holder to purchase an additional Share at a price of $1.25 for a period of two years from the date of issue. ImmunoPrecise will have the right to accelerate the expiry date of the warrants provided that ImmunoPrecise’s volume weighted average price trades at a price equal to or greater than $1.75 for a period of 20 consecutive days. In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after ImmunoPrecise issues a news release announcing that it has elected to exercise this acceleration right

Settlement with Crossbeta

ImmunoPrecise and Crossbeta Biosciences B.V (“Crossbeta”) have entered into a settlement agreement in connection with the previously announced letter of intent entered into by the parties. Under the terms of the settlement agreement, ImmunoPrecise has agreed to pay EUR 37,000 to Crossbeta, and either (i) issue to Crossbeta such number of common shares equal to EUR 40,700 divided by the Market Price of ImmunoPrecise’s shares or (ii) pay to Crossbeta a cash payment of EUR 40,700.


#148

Un collaborateur d’EspaceMC, Paul Andreola, s’ajoute au conseil d’administration d’ImmunoPrecise :

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that the annual general meeting (the “Meeting”) of the shareholders of
ImmunoPrecise Antibodies Ltd. (the “Company”) will be held at 704 – 595 Howe Street, Vancouver, BC,
V6C 2T5 on Tuesday, November 20, 2018 at 11:00 a.m. (PST) for the following purposes:
1. to set the number of directors at six (6) persons;
2. to elect Jennifer Bath, James Kuo, Greg Smith, Robert Beecroft, Robert Burke and Paul Andreola as
directors of the Company for the ensuing year;

Avec ses 30 années d’expérience, je suis sûr qu’il sera d’une aide précieuse pour aider la compagnie à adopter les bonnes stratégies entourant les marchés de capitaux. Il est aussi actionnaire important de la compagnie alors ses intérêts seront sans doute alignés avec ceux des actionnaires.


#149

Le marché a pas l’air d’accord avec toi en tout cas


#150

Il a rebondi exactement sur son support à 0.72$


#151

Si le marché était tout le temps d’accord avec moi, il n’y aurait jamais d’opportunité et ce ne serait pas un marché.

J’aime le fait que des détenteurs de la debenture convertible aient accepté de convertir à un prix de 1$ l’action pour 1.377M$ alors que le titre se transigeait sous les 0.80$. Les démarches pour convertir avaient été entreprise avant la récente chute mais de toute façon avec un horizon moindrement long terme, les fluctuations du marché ne changent rien à la thèse ni au potentiel de l’entreprise.


#152

Parfaitement d’accord avec toi, j’étais juste un peu amer que le titre soit down de 8-10% aujourd’hui. J’ai rien vu a date avec cette entreprise qui me fait peur.


#153

ImmunoPrecise Antibodies Ltd. Discusses Target Customer Base and Growth Drivers in New SNNLive Video Interview on StockNewsNow.com

LOS ANGELES, CA / ACCESSWIRE / November 20, 2018 / StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Jennifer Bath, Ph.D., CEO and President of ImmunoPrecise Antibodies Ltd. (TSX-V: IPA) (OTC PINK: IPATF), a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, according to the company’s website (see here: www.immunoprecise.com). The video interview was recorded on Thursday, October 18, 2018 at the Smallcap Discoveries Conference 2018 in Vancouver, BC.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

ImmunoPrecise Antibodies Ltd. - Therapeutic Antibody Discovery Company Discusses Target Customer Base and Growth Drivers

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery. ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hyridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

For more information about ImmunoPrecise Antibodies Ltd., please visit: www.immunoprecise.com

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.

info@stocknewsnow.com


#154

Achats d’initiés pour ajouter à son importante position :


#155

Bon signe. Est-ce qu’on s’attend à franchir des étapes importantes dans les prochains 6 mois?


#156

Il semble y avoir une tendance des grosses pharmaceutiques à vouloir sous-traiter, ce qui est bon signe pour un CRO comme IPA :

Bayer moves to refocus on its core pharma R&D, cutting 900 research jobs

n September, Reuters reported that Bayer had begun a monthslong review of its R&D programs in January, exploring whether drug-testing services could be outsourced to cheaper contractors. The company’s pharmaceutical R&D units underwent a major reorganization last November, with all its therapeutic areas being consolidated under one division.

In its latest statement, Bayer said that focusing on external work would be “an essential step” in the restructuring of its internal R&D activities.

“Resources freed up through the reduction of internal capacities are to be directed toward strengthening investment in collaborative research models and external innovations,” the company said.


#157

IPA_Initiation-2018-12-06_08_13_37.876.pdf (1,2 Mo)

Cormark lance une recherche sur Immunoprecise


#158

Achat de Paul A.


#159

Suivant son rebond à partir de son support à 0.72$, le titre est revenu à 0.94$ avant de retomber et de briser son support à 0.72$, prochain support est à 0.54$


#160

@Frederick_Chabot pourra peut-être nous garder informer

ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 7-10, 2019

VICTORIA, Jan. 3, 2019 (Canada NewsWire via COMTEX) – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE IPA) (OTC PINK IPATF) announced today IPA will be in San Francisco during the J.P. Morgan 37th Annual Healthcare Conference events running from January 7-10, 2019 in San Francisco, California.

Thirty-seven years ago, J.P. Morgan launched Wall Street’s premier investor conference focused exclusively on companies defining the healthcare industry. The J.P. Morgan Healthcare Conference brings industry leaders, emerging fast-growth companies, and members of the investment community together in the largest healthcare investment symposium to deliver presentations to global investors. This year, J.P. Morgan expects more than 450 companies, both public and private, to deliver presentations to more than 9,000 attendees.

Networking at the small, adjacent summits occurring simultaneously to the J.P. Morgan Healthcare Conference in San Francisco is ideal for connecting investors with industry leaders. ImmunoPrecise Antibodies, Ltd. CEO and President, Jennifer Bath, will be in attendance along with Jason Orloske, Vice President of Operations. The team will also include Frederick Chabot, Contact Financial, Paul Andreola, IPA Board Director, and Pascal Nigen, Managing Partner at Alpha Bronze.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.


#161

Oui ça risque d’être très prometteur